Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new global head of corporate affairs, as the obesity drugmaker faces growing pressure from U.S. President Donald Trump on drug pricing. Miley recently served as senior vice president of government affairs at U.S. pharmaceutical giant AbbVie. He posted a statement about his appointment on LinkedIn on Friday and Novo Nordisk shared the statement with Reuters.

A Novo spokesperson said on Saturday that Miley would join the company in early November, overseeing global communication and global public affairs. Novo is turning to an American executive with deep U.S. pharmaceutical experience to help navigate political risks under the Trump administration in the United States, its largest market.

NEW HIRE TO FOCUS ON RELAT

See Full Page